Inventor
Hans Loibner
Inventor
Vienna, AT
Overview
Patents· 29 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes27%
C07KPeptides19%
C12NMicroorganisms or enzymes9%
C12YEnzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
C07DHeterocyclic compounds1%
C07HSugars1%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
11,079,398Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples202110,995,147Preparations and methods for treating a GD2 positive cancer202110,716,833Method for producing ACE2 polypeptide202010,472,341Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases201910,294,305Method for treating a GD2 positive cancer20199,840,566'Preparations and methods for treating a GD2 positive cancer'20179,839,668'Compositions and methods for the treatment of diseases related to the renin-angiotensin-system'20179,777,068'Method for treating a GD2 positive cancer'20179,757,433'Modified ACE2 polypeptides'20179,684,004'Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples'20179,561,263'Treatment of inflammatory illnesses with ACE2'20179,186,373'SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer'20158,946,162'Treatment of tumors'20158,809,288'Method for increasing immunoreactivity'20148,586,319'Recombinant ACE2 polypeptide dimer'20138,444,974'Use of antibodies for the vaccination against cancer'20138,323,650'Method of treating lewis Y-expressing tumors'20128,241,864'Method for determining ACE2 activity'20128,153,135'Polysaccharide-polypeptide conjugate'20128,062,625'Cancer immunotherapy predictive parameters'20118,034,338'Immunogenic recombinant antibody'20117,759,464'N-glycosylated antibody'20107,691,372'Use of antibodies for the vaccination against cancer'20107,615,226'Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant'20097,527,789'Use of a preparation based on an antibody directed against a tumor-associated glycosylation'20096,956,119'Polysaccharide-polypeptide conjugate'20055,562,903'Humanized antibodies that recognize difucosyl Lewis blood group antigens Y-6 and B-7-2'19965,523,085'Monoclonal antibody in destruction of small cell lung carcinoma'19964,503,046'1-Nitro-aminoglycoside derivatives, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticals'1985Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1985–2021Based in Vienna, AT· patent location history
2005–2017Patents assigned to LOIBNER HANS (13)· patent assignee history
2009–2013Patents assigned to IGENEON KREBS IMMUNTHERAPIE (4)· patent assignee history
2012–2017Patents assigned to SCHUSTER MANFRED (9)· patent assignee history
2012–2017Patents assigned to JANZEK-HAWLAT EVELYNE (4)· patent assignee history
2013–2021Patents assigned to APEIRON BIOLOGICS AG (10)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| LOIBNER HANSself | 13 | 2005–2017 |
| APEIRON BIOLOGICS AG | 10 | 2013–2021 |
| SCHUSTER MANFRED | 9 | 2012–2017 |
| IGENEON KREBS IMMUNTHERAPIE | 4 | 2009–2013 |
| JANZEK-HAWLAT EVELYNE | 4 | 2012–2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| Vienna, AT | 29 | 1985–2021 |